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Edited by Varda RotterAbstract Genistein is the most abundant isoﬂavone of soybeans
and has been shown to cause growth arrest in various human
cancer cell lines. However, the precise mechanism for this is still
unclear. We report here that the growth arrest and DNA
damage-inducible gene 45 (gadd45) gene is induced by genistein
via its promoter in a DU145 human prostate cancer cell line. The
binding of transcription factor nuclear factor-Y to the CCAAT
site of the gadd45 promoter appears to be important for this
activation by genistein.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Nuclear factor-Y1. Introduction
Many epidemiological studies have suggested that the
dietary intake of soybeans is associated with a low risk for
developing certain cancers [1,2]. Genistein (4,5,7-trihydroxyi-
soﬂavone) is the most abundant isoﬂavonic component of
soybeans. Others and we have reported that genistein arrests
cell cycle progression at the G2/M or G1/S phases [3,4].
However, the mechanism responsible for this arrest is not
understood.
Several studies have shown that gadd45 causes cell cycle
arrest [5–7], and is involved in apoptosis [8] and genomic sta-
bilization [9]. In addition, it is known to be a target gene of the
tumor suppressor gene p53. In this report, we demonstrate that
genistein induces gadd45 activation via its promoter, through a
p53-independent pathway.* Corresponding author. Fax: +81-75-241-0792.
E-mail address: ysowa@koto.kpu-m.ac.jp (Y. Sowa).
Abbreviations: gadd45, growth arrest and DNA damage-inducible
gene 45; NF-Y, nuclear factor-Y; C/EBP, CCAAT/enhancer-binding
protein
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2.1. Reagents
Genistein was obtained from Fujikko (Tokyo, Japan). It was dis-
solved in dimethylsulfoxide (DMSO) and diluted to ﬁnal concentra-
tions in each culture medium used (below).
2.2. Cell culture and cell growth
DU145 cells (a p53-mutant human prostate cancer cell line) were
maintained in RPMI1640 (Nissui Pharmaceutical Co. Ltd., Tokyo,
Japan) supplemented with 10% fetal bovine serum (MP Biomedicals,
Irvine, CA, USA). Cells (3 104) were seeded and 24 h later treated
with various concentrations of genistein. Numbers of cells were
counted every 24 h. Data were analyzed using two-tailed Student’s t
tests and diﬀerences were considered to be statistically signiﬁcant from
the controls at P < 0:05.
2.3. Cell cycle analysis
Unsynchronized cells were exposed to genistein for 24 h and then
harvested and ﬁxed in 70% ethanol. After treating with RNase A and
propidium iodide, DNA contents were measured using FACSCalibur
(Becton Dickinson, Inc., Franklin Lakes, NJ, USA). The ModFit LT
V2.0 software package (Verity Software, Topsham, ME, USA) was
used to analyse the data.
2.4. Protein assay
Gadd45 protein was analyzed by immunoblotting. Cells were lyzed
with 20 mM Tris buﬀer (pH 8.0) containing 137 mM NaCl, 2 mM
EDTA, 10% (v/v) glycerol, 1 mM phenylmethylsulfonyl ﬂuoride, 10
lg/mL leupeptin, 10 lg/mL aprotinin, and 1% (v/v) Triton X-100 [10].
Each protein (75 lg) was separated by electrophoresis on polyacryl-
amide gels. Transferred PVDF membranes were probed with mono-
clonal antibodies for gadd45 (Santa Cruz Biotech., Inc., Santa Cruz,
CA, USA) and for b-actin (Oncogene Res. Prod., San Diego, CA,
USA) as a loading control. Signals were detected using an ECL
Western blot analysis system (Amersham Biosciences, Buckingham-
shire, UK).
2.5. RNA isolation and Northern blot analysis
The isolation of total RNA was as described [11]. Each aliquot of
RNA (10 lg) was separated by electrophoresis on a 1.5% agarose gel,
transferred to a membrane (Gene Screen Plus; DuPont New England
Nuclear, Boston, MA, USA), and hybridized with an [a-32P]dCTP-
labeled XbaI/HindIII fragment from pCMV-45 (kindly provided by
Dr. A.J. Fornace, Jr.). Hybridization was carried out at 68 C in
PerfectHyb hybridization solution (Toyobo Co., Ltd., Osaka, Japan).
The same membrane was rehybridized with an [a-32P]dCTP-labeled
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probeblished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of genistein on the growth and cell cycle of DU145 cells.
(A) One day after inoculation of DU145 cells, genistein dissolved in
DMSO was added at 20, 50, 75 or 100 lM, and cell growth was
compared with a control culture with equivalent DMSO alone.
Numbers of cells were counted every 24 h. The data represent means of
56 T. Oki et al. / FEBS Letters 577 (2004) 55–59(Clontech Laboratories, Inc., Palo Alto, CA, USA) as a loading
control.
2.6. Construction of plasmid DNA
Constructions of the human gadd45 promoter–luciferase fusion
plasmids, pG45-luc, pG45-1325, pG45-817, pG45-234, pG45-81, and
pG45-10, were as previously described [11]. A QuikChange site-di-
rected mutagenesis kit (Stratagene Cloning Systems, Co., La Jolla,
CA, USA) was used to generate point mutations at the Oct-1 or
the CCAAT site of the pG45-234 reporter plasmids. The primer
used to mutate the Oct-1 site in the region between )75 and )62
bp of the pG45-234 plasmid was 50-CCA ATG GCC AAG CTG
CAT GCA AGC GAG GCG GAA GGT GGT TGG-30 (the
mutated nucleotides are underlined). The primer used to mutate the
CCAAT site in the region between )55 and )46 bp was 50-GAG
GCG GAA GGT GGT TTT ATG AGG GTT GGC AGG ATA
ACC C-30 (the mutated nucleotides are underlined). The vacant
control luciferase plasmid pGVB2 was purchased from Nippon
Gene (Tokyo, Japan).
2.7. DNA transfection and luciferase assay
After DU145 cells had been cultured for 24 h, 0.5 lg of reporter
plasmid DNA was transfected using a CellPhect transfection kit
(Amersham Pharmacia Biotechnology, Inc., Piscataway, NJ, USA).
Twenty-four hours after transfection, the cells were treated with or
without genistein and 24 h later the cells were collected for luciferase
assay. This was measured on cell lysates as described [11], and each was
normalized for the amount of protein in the cell lysates, measured
using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules,
CA, USA). Data were analyzed using two-tailed Student’s t tests and
diﬀerences were considered statistically signiﬁcant from controls at
P < 0:05.
2.8. Electrophoretic mobility shift assay (EMSA)
Annealed double-stranded oligonucleotides containing the se-
quence of the CCAAT site (50-GCA TAG CCC AAT GGC CAA
GC-30), the mutated CCAAT site (50-GCA TAG CCT TGT GGC
CAA GC-30; mutated oligonucleotides are underlined), the Oct-1
site (50-AGC AGG CTG ATT TGC ATA GC-30), and the mu-
tated Oct-1 site (50-AGC AGG CTG GCT TGC ATA GC-30;
mutated oligonucleotides are underlined) between positions )234
and )81 bp were labeled with [a-32P]dCTP and used as probes.
Competition reactions were performed using a 100- and 200-fold
molar excess of unlabeled oligonucleotides. Nuclear extracts (9 lg)
treated with or without 75 lM genistein were incubated in a 20
lL reaction volume containing the appropriate buﬀer and 1 lg of
poly(dI–dC). An [a-32P]dCTP-labeled probe was added and the
reaction mixture was incubated. In supershift experiments, anti-
bodies against NF-YA, NF-YB, C/EBP, and Oct-1 (Santa Cruz
Biotechnology) were preincubated with nuclear extracts before
addition of the probe.triplicate experiments and the bars show SDs. (B) Unsynchronized
cells were incubated in the presence or absence (DMSO alone) of 75
lM genistein for 24 h and the DNA content of the cells was determined
by ﬂow cytometry.3. Results
3.1. Genistein blocks cell growth at the G2/M phase of DU145
human prostate cancer cells
We ﬁrst examined the eﬀect of genistein on the growth of
DU145 cells. Fig. 1A shows the growth rate of DU145 cells
in the presence or absence of various concentrations of
genistein. A signiﬁcant dose-dependent inhibition of cell
growth was observed. After 72 h, cell growth was inhibited
to 51%, 12%, 10%, and 8% of controls by genistein at 20, 50,
75, and 100 lM, respectively. Next, we examined changes in
the distribution of DNA content after 24 h incubation in the
presence or absence of genistein (75 lM) using ﬂow cytom-
etry. As shown in Fig. 1B, signiﬁcant G2/M cell cycle arrest
was observed in cells treated with genistein. Treatment with
75 lM genistein changed the percentages of cells in the G1,
S, and G2/M phases from 39%, 36%, and 25% to 4%, 15%,
and 81%, respectively.3.2. Genistein induces production of the Gadd45 protein and
mRNA in DU145 cells
As shown in Fig. 2A, we found that treatment with genistein
stimulated the production of Gadd45 protein in a dose-de-
pendent manner. We next measured the gadd45 mRNA level
in genistein-treated DU145 cells using Northern blot analysis.
Twenty-four hours exposure to genistein induced 1.3-, 3.7-,
4.7-, and 4.7-fold of gadd45 mRNA relative to control at 20,
50, 75, or 100 lM, respectively (Fig. 2B). A time course study
showed that the gadd45 mRNA was induced by 6 h after
treatment with 75 lM genistein (Fig. 2C).
3.3. Genistein stimulates gadd45 promoter activity
Next, we investigated whether genistein could stimulate the
activity of the gadd45 gene promoter. As shown in Fig. 3A,
Fig. 2. The gadd45 gene expression was induced by genistein in DU145
cells. (A) Western blot analysis of DU145 cells treated with various
concentrations of genistein for 24 h. (B) Northern blot analysis of
gadd45 mRNA from DU145 cells treated with various concentrations
of genistein for 24 h. The mRNA level of gadd45 was standardized
against that of glyceraldehyde-3-phosphate dehydrogenase. (C)
Northern blot analysis of gadd45 mRNA from DU145 cells treated
with 75 lM genistein for the indicated times.
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manner. We then determined which regions of the gadd45
promoter were responsive to genistein. For this purpose, we
prepared various lengths of 50-deletion constructs of the
gadd45 promoter–luciferase fusion plasmids (Fig. 3B). As
shown in Fig. 3C, the response to genistein decreased with
deletion of the region between )234 and )81 bp. This suggests
that a genistein-responsive element exists within 153 bp relative
to the transcriptional start site. This region (from )234 to )81
bp) contains Oct-1 and CCAAT sites, which are conserved
among species [12]. Therefore, this region appears to be es-
sential for the activation of gadd45 by genistein. To determine
the genistein-responsive site of pG45luc-234 precisely, weFig. 3. Activation of gadd45 promoter activity in DU145 cells by
treatment with genistein. (A) DU145 cells were transiently transfected
with gadd45–luciferase fusion plasmids (pG45-luc) or with vacant
control luciferase plasmids (pGVB2), and luciferase activities were
measured after incubation with medium containing various concen-
trations of genistein for 24 h. The data represent means of triplicate
experiments and the bars show SDs. **P < 0:01. (B) Prepared plasmid
constructs are shown. Various 50-deletion mutants of pG45-luc and
pG45-234 reporter plasmids harboring point mutations in the Oct-1
site, closed circle, or the CCAAT site, closed square, were used to
identify the genistein-responsive element. (C) Deletion analysis of the
gadd45 promoter. DU145 cells were treated in the presence or absence
(DMSO alone) of 75 lM genistein. The response to genistein decreased
with deletion of the region between )234 and )81 bp. (D) Mutation
analysis of the gadd45 promoter. The response to genistein decreased
because of the point mutation at the CCAAT site, whereas there was
little change caused by the point mutation at the Oct-1 site.
cprepared two constructs, pG45luc-234mOct-1 and pG45luc-
234mCCAAT, which contained point mutations at the Oct-1
or the CCAAT site of pG45luc-234, respectively (Fig. 3B). As
shown in Fig. 3D, the response to genistein decreased because
of the point mutation at the CCAAT site, while there was little
change resulting from the point mutation at the Oct-1 site.
Fig. 4. Binding of nuclear proteins to the Oct-1 site or the CCAAT site
of the gadd45 gene. EMSAs were carried out with nuclear extracts
prepared from DU145 cells. (A) Speciﬁc binding of NF-Y to the
CCAAT site. Treatment with 75 lM genistein enhanced the binding of
NF-Y to the CCAAT site (lanes 1 and 2). (B) Speciﬁc binding of Oct-1
to the Oct-1 site. Treatment with 75 lM genistein did not result in any
diﬀerence of the binding of nuclear protein Oct-1 to the Oct-1 site
(lanes 1 and 2).
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We examined whether genistein changed the binding of
transcription factors to the Oct-1 and the CCAAT sites. The
Oct-1 and the CCAAT sites of the promoter region of gadd45
are of great signiﬁcance [7,11,13]. The transcription factors
Oct-1 and NF-Y are known to bind mainly to Oct-1 and
CCAAT sites, respectively. As shown in Fig. 4A, 75 lM gen-
istein increased the binding of NF-Y to the CCAAT site, but
did not increase the amount of NF-Y protein (data not
shown). On the other hand, genistein did not produce any
change in the binding of transcription factor Oct-1 to the Oct-1
site (Fig. 4B).4. Discussion
Others and we have shown that genistein causes G2/M arrest
in various cancer cell lines [3,4,14]. Choi et al. [14] reported
that the induction of p21/WAF1 and the reduction of cyclin B1
by genistein cause inhibition of the kinase activities of cdk2
and cdc2 in human breast cancer cell lines. However, we did
not observe a reduction of cyclin B1 by genistein in DU145
cells, although weak induction of p21 protein was observed
(data not shown). In this study, we showed that genistein in-
duces gadd45 gene expression in this p53-mutant human
prostate cancer cell line DU145. Similar results were observed
in the p53-null human prostate cancer cell line PC3 (data not
shown). Gadd45 is a target gene of p53 and in addition a p53-
independent pathway has also been reported [7,11,12,15].
Others and we have reported that the Oct-1 and the CCAAT
sites of the promoter region are important for induction of the
gadd45 gene [7,11,13]. In this study, we found that the geni-
stein-responsive element is the CCAAT site. The results of
EMSA (Fig. 4A) suggest that this induction of gadd45 by
genistein is caused by the increased binding of NF-Y to the
CCAAT site of the promoter region. Shimizu et al. [16] re-
ported that genistein induced the bone sialoprotein (BSP) gene
through its promoter and that the CCAAT site of the BSP
promoter region was of signiﬁcance. The CCAAT site of both
the BSP and gadd45 genes may thus be important for activa-
tion by genistein.
The Gadd45 protein is reported to have roles in cell cycle
regulation [5–7], apoptosis [8], and genomic stability [9].
Therefore, ﬁnding an agent that transcriptionally upregulates
this gene in cancer cells may contribute to new strategies for
the prevention of or therapy for cancer, which we have termed
‘gene-regulating chemoprevention or chemotherapy’ [17,18]. In
this sense, genistein, which activates gadd45 gene expression,
would represent a gene-regulating chemopreventive agent.
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